EU Accelerated Assessment Tracker
Fast-Track Success For Janssen-Cilag’s Teclistamab
Janssen-Cilag's EU filing for teclistamab is being reviewed under the European Medicines Agency’s accelerated assessment procedure. The outcome of Sanofi’s request relating to nirsevimab is not yet in the public domain.